Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion. | Journal of Immune Based Therapies and Vaccines Original research BioMed Central Open Access CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion Anders E Pedersen 1 and Franca Ronchese2 Address department of International Health Immunology and Microbiology The Panum Institute University of Copenhagen Denmark and 2Malaghan Institute of Medical Research Wellington New Zealand Email Anders E Pedersen - elmpedersen@ Franca Ronchese - fronchese@ Corresponding author Published 29 July 2007 Received 10 May 2007 Journal of Immune Based Therapies and Vaccines 2007 5 9 doi 1476-8518-5-9 Accepted 29 July 2007 This article is available from http content 5 1 9 2007 Pedersen and Ronchese licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Dendritic cells DCs are potent antigen-presenting cells and critical for the priming of CD8 T cells. Therefore the use of these cells as adjuvant cells has been tested in a large number of experimental and clinical vaccination studies in particular cancer vaccine studies. A number of protocols are emerging that combine vaccination with CTL expanding strategies such as . blockade of CTLA-4 signalling. On the other hand the lifespan and in vivo survival of therapeutic DCs have only been addressed in a few studies although this is of importance for the kinetics of CTL induction during vaccination. We have previously reported that DCs loaded with specific antigens are eliminated by antigen specific CTLs in vivo and that this elimination affects the potential for in vivo CTL generation. We now show that CTLA-4 blockade increases the number of DC vaccine induced LCMV gp33 specific .
